Please login to the form below
haematological cancer
This page shows the latest haematological cancer news and features for those working in and with pharma, biotech and healthcare.
Keytruda hits primary endpoint in confirmatory lymphoma trial
It was the first green light for the drug in a haematological cancer, and Keytruda has since gone on to receive approval in primary mediastinal B-cell lymphoma, a rare form ... Patients with classical Hodgkin lymphoma are generally young and when they do
Latest news
-
AstraZeneca’s Calquence impresses in previously untreated CLL
broad range of haematological cancer indications.
-
AstraZeneca wins FDA approval for Calquence in chronic lymphoma
range of haematological cancer indications.
-
Roche agrees $1.4bn takeover of fibrosis specialist Promedior
That mechanism suggests PRM-151 could have potential in a range of diseases characterised by fibrosis, including myelofibrosis – a haematological cancer that results in scarring of the bone marrow and severe ... With our proven track record in IPF with
-
AZ’s Calquence threatens Imbruvica with new leukaemia data
blockbuster product with sales of $3.6bn in 2018 and a target of $4.4bn this year across a broad range of haematological cancer indications.
-
Celgene boosts haematology pipeline with $7bn Impact Bio deal
and downgraded sales estimates for its haematological cancer drugs.
AstraZeneca’s Calquence impresses in previously untreated CLL
Roche agrees $1.4bn takeover of fibrosis specialist Promedior
Celgene boosts haematology pipeline with $7bn Impact Bio deal
More from news
Approximately 2 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological malignancies. ... Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific
Deal Watch September 2016
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Manager
-
Salary TBC
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Planner
-
Salary TBC
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- OPEN Health Starring in the Top 100 North American Healthcare Agencies of 2021
- Gilead reveals real-world data for COVID-19 drug Veklury
- EFPIA appoints Hubertus von Baumbach as president
- COUCH Health Engages Mark Duman as Chief Strategy Officer
- New data shows benefits for presymptomatic SMA patients treated with Zolgensma
- Sanofi’s oral therapy Aubagio approved in the EU for paediatric MS patients
- Diversity and inclusion in clinical trials
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Pfizer takeover rumour ignites Amarin shares
- Oxford University, Prenetics to advance COVID-19 rapid testing for other infectious diseases
- Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma
- BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
Latest intelligence
- The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
- By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
- How early-stage clinical research is facilitating the new wave of personalised medicines
- By Jorg Taubel...
- Patient diversity in clinical trials needs to be centre stage
- By Danny Buckland...
